modelCiclopirox
Extends from Pharmacolibrary.Drugs.ATC.G.G01AX12.
Information
| name: | Ciclopirox | |
| ATC code: | G01AX12 | route: | topical |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 10 | L |
| clearance: | 1 | L/h |
| other parameters in model implementation | ||
Ciclopirox is a synthetic antifungal agent used mainly in topical formulations to treat dermatophytoses, candidiasis, and seborrheic dermatitis. It is not typically used systemically and is approved for topical use in various countries.
Pharmacokinetics
Estimated pharmacokinetic parameters for topical application in adults; no published clinical pharmacokinetic studies available for oral, intravenous, or systemic administration.
References
Gupta, AK, et al., & Foley, KA (2014). Topical therapy for toenail onychomycosis: an evidence-based review. American journal of clinical dermatology 15(6) 489–502. DOI:10.1007/s40257-014-0096-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25257931
Hafeez, F, et al., & Maibach, H (2014). Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers. Drug development and industrial pharmacy 40(6) 838–844. DOI:10.3109/03639045.2013.788016 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23600655
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)